Back to Research & Science
Research & Science•••9 min read

Stopping GLP-1: Weight Regain and Maintenance

What happens after stopping semaglutide or tirzepatide? Withdrawal trial results, limits of tapering claims, and questions for a clinician-led plan.

PeptIQ Team
Peptide Research & Education
Weight Regain After Stopping GLP-1: What to Know

PeptIQ app

Track your peptide protocols in PeptIQ

Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.

Get the appOpen web app

iOS, Android, and web

Research supplier

Semaglutide listings are for laboratory / research use only — not for human consumption.

Also mentioned

Research use only. Partner link. PeptIQ may earn a referral fee. Not medical advice.

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist

TL;DR

Weight regain after stopping GLP-1 treatment is common in withdrawal studies, but an average is not a personal forecast. Semaglutide and tirzepatide trials support planning for ongoing care. They do not establish a self-directed taper, a guaranteed way to prevent regain, or a deadline when everyone’s appetite returns.

If you are considering stopping because of cost, side effects or reaching a goal, make that reason the starting point of a clinical conversation. This PeptIQ.io guide separates what researchers measured from what an individual still needs to decide. Updated October 30, 2026.

Talk to a licensed clinician before starting, stopping or changing treatment. The purpose here is to help you ask better questions, not to choose a medication plan from a chart.

What Happens After Stopping Semaglutide?

The STEP 1 extension followed an exploratory subset of 327 participants after the main trial. Both study medication and the structured lifestyle intervention ended. Over the following year, participants previously assigned semaglutide regained about two-thirds of their earlier weight loss, on average. Their average weight remained below the original baseline.

That fraction refers to weight previously lost, not total body weight. It also does not mean every participant regained the same amount. Because this was a subset followed after both interventions ended, it cannot isolate the effect of withdrawing medication from the effect of withdrawing structured support.

Use this study to understand why a follow-up conversation matters. Do not turn its group average into a personal target, a prediction of failure, or a reason to change treatment without your prescriber.

What Happens After Stopping Tirzepatide?

SURMOUNT-4 used a randomized withdrawal design. After an initial treatment period, 670 adults were assigned either to continue tirzepatide or switch to placebo. Participants had overweight or obesity and did not have diabetes.

Over the next 52 weeks, average weight increased 14.0% in the placebo group and fell a further 5.5% in the continuing-treatment group. Those percentages use weight at randomization as their starting point, after the initial loss. They are not percentages of the weight already lost.

This supports a role for continued treatment in maintaining weight reduction in that study population. It does not tell every person to remain on the same treatment indefinitely: individual benefit, tolerability and circumstances still need review. For background on the medicine, see what tirzepatide is.

PeptIQ.io / Maintenance / 01

Know where the percentage starts.

Two withdrawal studies, two ways of reporting change. These numbers are not a head-to-head drug comparison.

Follow-up after withdrawal

STEP 1 extension

About two-thirds

of earlier weight loss regained on average over the following year

Medication and structured lifestyle intervention both ended.

Randomized withdrawal

SURMOUNT-4

+14.0% / −5.5%

weight change: placebo / continued tirzepatide over 52 weeks

Percentages start at randomization, after initial weight loss.

A fraction of earlier loss and a percentage of current weight have different denominators.

Evidence for a better conversation.Oct 2026
Sources: Wilding et al., STEP 1 extension (2022); Aronne et al., SURMOUNT-4 (2024). Study averages, not personal forecasts. Primary sources linked in the article.

Does Lifestyle Support Change the Picture?

The STEP 4 randomized trial helps answer a narrower question. After an initial semaglutide period, 803 participants continued semaglutide or switched to placebo, while both groups continued lifestyle intervention. During the randomized follow-up, the continuing group lost a further 7.9% on average; the placebo group gained 6.9%, measured from randomization.

That result shows that structured lifestyle support did not erase the difference between continued treatment and withdrawal in this trial. It does not show that support is useless, nor that every person will have the average result. It also does not test every possible approach to maintenance.

The National Institute of Diabetes and Digestive and Kidney Diseases explains that eating habits and physical activity remain part of weight management and may help limit regain after stopping. Ask what support fits your health, preferences and available resources. Avoid interpreting a medication change as a test of whether you can succeed through effort alone.

How to Read Weight-Regain Headlines

Before sharing a result, check three details: the starting point, the comparison, and the outcome. A percentage without its denominator can tell a very different story from the study itself.

Detail to checkQuestion to ask
Starting pointIs this change from original weight, weight after initial treatment, or a fraction of earlier loss?
ComparisonDid people continue treatment, switch to placebo, or simply enter follow-up?
Other supportDid the same lifestyle support continue in both groups?
ParticipantsWho entered the trial, and who qualified for the withdrawal phase?
OutcomeIs the result about weight, appetite, health markers or quality of life?

These trials were not a head-to-head comparison of stopping semaglutide versus stopping tirzepatide. Lining up their percentages does not establish which medicine causes more rebound. Different study designs and starting points can make a neat-looking comparison misleading.

A useful summary to share is: “The study found an average pattern under these conditions.” Add the conditions before making a claim about what will happen to someone else. This leaves room for both the result and its limits.

Can Tapering Prevent Weight Regain?

The withdrawal trials discussed above do not establish a tapering method that reliably prevents regain. A comparison of continued treatment with withdrawal is a different experiment from a comparison of several ways of stopping.

If you encounter a claim that a particular taper guarantees maintenance, ask for the actual study. Did it include a comparison group? How were participants selected? How long were they followed? Were outcomes measured for everyone who started, or only for people who returned? A compelling testimonial cannot answer those design questions.

Bring the claim to your prescriber rather than using it as instructions. Useful questions include: “Does this evidence apply to my reason for treatment?” and “What would we monitor if my treatment changes?” This guide offers no tapering schedule, restart instructions or medication substitutions.

Build a Maintenance Conversation Around Your Situation

NIDDK describes treatment duration as a decision that depends on benefits and adverse effects; some people may be advised to continue long term. That does not remove the need for an individual review. Prepare a short agenda around the decision you actually face:

  • Reason for considering a change: cost, unwanted effects, access, a new health concern, or a personal preference.
  • What you hope to preserve: a health improvement, everyday functioning, comfort around eating, or another goal you can explain.
  • What feels difficult: symptoms, food-related distress, affordability, or keeping appointments.
  • What you need clarified: who will review the plan, how to contact them, and what information to bring.

Keep the agenda specific. “I want a plan I can afford” and “I am worried about this symptom” lead to different discussions, even if both initially sound like “I want to stop.” You do not need to arrive with a proposed replacement or a precise numerical target.

For example, a useful appointment note could read: “I am considering a change because of cost. My main concern is preserving the health improvement we discussed. What options are appropriate, and how will we review the outcome?” This is a communication example, not evidence that a particular option is suitable.

PeptIQ.io / Maintenance / 02

Bring questions. Build a plan together.

A short appointment agenda can keep the conversation focused on your circumstances.

01 / Your reason

Why consider a change?

Describe the concern: cost, unwanted effects, access or personal preference.

02 / Your priorities

What matters to you?

Name the health improvement or daily-life goal you want to discuss.

03 / Your follow-up

How will care continue?

Ask who to contact, what to bring and how the plan will be reviewed.

Evidence for a better conversation.Oct 2026
Editorial conversation aid, not a treatment algorithm or a validated assessment. Clinical decisions belong with a licensed clinician.

What to Record Before a Follow-Up

Use a brief record if it helps you describe events accurately. Separate what happened from what you think caused it. “My appetite felt different after this date” is an observation; “the medicine has stopped working” is an interpretation that needs assessment.

Possible notes include the reason for the appointment, symptoms in your own words, questions about eating or activity, and any measurements your clinician has asked you to collect. Include practical barriers as well as health concerns. Leave room for the clinician to decide which details matter.

Do not turn tracking into automatic treatment rules. A change in one number should not become a self-written instruction to stop, restart or replace a prescription. Ask your clinician to define the follow-up process for your circumstances, including what warrants earlier contact. If keeping detailed records causes distress, discuss a simpler approach.

Approved Medicines and Research Materials Are Different

The FDA’s guidance on unapproved GLP-1 products explains that unapproved versions have not undergone its premarket review for safety, effectiveness and quality. Compounded drugs are not FDA approved, and the agency warns about products sold for research purposes being used by people.

Do not read a study of a prescription medicine as validation of a research product with a similar name. A laboratory listing is not a replacement treatment or a way to manage an interruption in care. Discuss access problems with your licensed clinician. The partner listing below is explicitly for research materials and is separate from the clinical evidence in this guide.

How PeptIQ.io Helps

The PeptIQ.io download page provides access to the companion app. Use educational reading to prepare questions for your care team, and keep clinical decisions with a licensed professional. An app or an answer from PeptIQ AI cannot establish why your weight changed or determine whether stopping treatment is appropriate.

For questions focused on intrusive food thoughts rather than weight, read GLP-1 food noise. For the broader medication landscape, see peptides for weight loss. Keeping the question clear helps you choose the relevant evidence instead of treating every outcome as interchangeable.

Talk to a Licensed Clinician

Talk to a licensed clinician about your reason for considering a change and the follow-up you need. Ask: “What are we trying to maintain, what choices fit my situation, and how will we decide whether the plan is working?” Take the unanswered questions from this guide to that discussion. No article can supply your medical history or make that decision for you.

Semaglutide research materials (partner)

Blank Peptides lists Semaglutide for laboratory / research use only — not for human consumption.

View Semaglutide research listing. Use code PEPTIQ for 10% off. Affiliate disclosure: PeptIQ.io may earn a referral fee. Not medical advice.

Frequently Asked Questions

Q: Will I regain all the weight after stopping a GLP-1?

A: That cannot be predicted from a group average. Withdrawal studies show regain is common, but they do not establish the same outcome for every individual. Discuss follow-up before making a change.

Q: What does “two-thirds regained” mean?

A: In the STEP 1 extension, it described the average fraction of earlier weight loss regained over the following year. It did not mean two-thirds of total body weight.

Q: Does tapering semaglutide prevent regain?

A: The withdrawal trials reviewed here do not establish that claim or provide a validated tapering method. Ask your prescriber to evaluate any proposed approach and its evidence.

Q: Do I need treatment forever?

A: There is no universal answer. Long-term care can be appropriate, but benefits, unwanted effects, preferences and access need individual review with a licensed clinician.

Q: Can I compare semaglutide and tirzepatide rebound percentages?

A: Not as a direct ranking. These trials used different designs and starting points. A fair comparison needs more than placing percentages beside each other.

Q: What should I bring to a maintenance appointment?

A: Bring your reason for considering a change, your main concern, relevant observations and questions about follow-up. You do not need to invent a treatment plan before asking for help.

Related Guides

This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.

For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.

Share this article

Track Your Peptide Protocols

Use PeptIQ to log injections and vial supply, use peptiq.io calculators for math on the web, and keep protocols organized.

Stay ahead of the peptide conversation

Weekly-ish notes on new research, wiki trends, and practical tracking tips. No spam — unsubscribe anytime.

Educational updates only — not medical advice. Privacy